Quality assurance of radiation therapy after breast-conserving surgery among patients in the BOOG 2013-08 trial.

Autor: Wintraecken VM; GROW - School for Oncology and Reproduction, Maastricht University, Maastricht, the Netherlands; Department of Surgery, Maastricht University Medical Centre+, Maastricht, the Netherlands. Electronic address: veerle.wintraecken@mumc.nl., Boersma LJ; Department of Radiation Oncology (Maastro), GROW School for Oncology and Reproduction, Maastricht University Medical Centre+, Maastricht, the Netherlands., van Roozendaal LM; Department of Surgical Oncology, Zuyderland Medical Center, Sittard-Geleen, the Netherlands., de Vries J; Department of Medical and Clinical Psychology, Tilburg University, Tilburg, the Netherlands; Board member Adrz, Goes, the Netherlands., van Kuijk SMJ; Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre+, Maastricht, the Netherlands., Vane MLG; GROW - School for Oncology and Reproduction, Maastricht University, Maastricht, the Netherlands; Department of Surgery, Maastricht University Medical Centre+, Maastricht, the Netherlands., van Dalen T; Division of Surgical Oncology, Diakonessenhuis Hospital, Utrecht, the Netherlands; Department of Surgery, Erasmus Medical Centre, Rotterdam, the Netherlands., van der Hage JA; Division of Surgical Oncology, Leids University Medical Center, Leiden, the Netherlands., Strobbe LJA; Division of Surgical Oncology, Canisius-Wilhelmina Hospital, Nijmegen, the Netherlands., Linn SC; Division of Medical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands., Lobbes MBI; GROW - School for Oncology and Reproduction, Maastricht University, Maastricht, the Netherlands; Department of Radiology and Nuclear Medicine, Maastricht University Medical Centre, Maastricht, the Netherlands; Department of Medical Imaging, Zuyderland Medical Center, Sittard-Geleen, the Netherlands., Poortmans PMP; Department of Radiation Oncology, Iridium Network, Antwerp, Belgium; Faculty of Medicine and Health Sciences, University of Antwerp, Belgium., Tjan-Heijnen VCG; GROW - School for Oncology and Reproduction, Maastricht University, Maastricht, the Netherlands; Division of Medical Oncology, Maastricht University Medical Centre, Maastricht, the Netherlands., van de Vijver KKBT; Department of Pathology, Ghent University Hospital, Ghent, Belgium; Department of Diagnostic Sciences, Cancer Research Institute Ghent (CRIG), Ghent University, Ghent, Belgium; Center for Gynecological Oncology Amsterdam (CGOA), Department of Gynecology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands., Westenberg AH; Radiation Oncology, Radiotherapiegroep location Arnhem, Arnhem, the Netherlands., de Wilt JHW; Division of Surgical Oncology, Radboud University Medical Centre, Nijmegen, the Netherlands., Smidt ML; GROW - School for Oncology and Reproduction, Maastricht University, Maastricht, the Netherlands; Department of Surgery, Maastricht University Medical Centre+, Maastricht, the Netherlands., Simons JM; GROW - School for Oncology and Reproduction, Maastricht University, Maastricht, the Netherlands; Department of Radiotherapy, Erasmus Medical Centre, Rotterdam, the Netherlands.

Publikováno v: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology [Radiother Oncol] 2024 Feb; Vol. 191, pp. 110069. Date of Electronic Publication: 2023 Dec 21.

Conditional regional recurrence risk: The effect of event-free years in different subtypes of breast cancer.

Autor: Vane MLG; Department of Surgical Oncology, Maastricht University Medical Centre, Maastricht, the Netherlands; GROW - School for Oncology and Developmental Biology, Maastricht University Medical Centre, the Netherlands. Electronic address: marissa.vane@gmail.com., Moossdorff M; Department of Surgical Oncology, Maastricht University Medical Centre, Maastricht, the Netherlands., van Maaren MC; Department of Research, Netherlands Comprehensive Cancer Organisation, Utrecht, the Netherlands; Department of Health, Technology and Services Research. Technical Medical Centre, University of Twente, Enschede, the Netherlands., van Kuijk SMJ; Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre, Maastricht, the Netherlands., van Nijnatten TJA; Department of Radiology and Nuclear Medicine, Maastricht University Medical Centre, Maastricht, the Netherlands., van Roozendaal LM; Department of Surgical Oncology, Maastricht University Medical Centre, Maastricht, the Netherlands., Boerma EG; Department of Surgery, Zuyderland Hospital, Heerlen, the Netherlands., de WIlt JHW; Department of Surgical Oncology, Radboud University Medical Centre, Nijmegen, the Netherlands., Smidt ML; Department of Surgical Oncology, Maastricht University Medical Centre, Maastricht, the Netherlands; GROW - School for Oncology and Developmental Biology, Maastricht University Medical Centre, the Netherlands.

Publikováno v: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology [Eur J Surg Oncol] 2021 Jun; Vol. 47 (6), pp. 1292-1298. Date of Electronic Publication: 2020 Nov 27.

Conditional local recurrence risk: the effect of event-free years in different subtypes of breast cancer.

Autor: Moossdorff M; Department of Surgical Oncology, Maastricht University Medical Centre, P.O. Box 5800, 6202 AZ, Maastricht, The Netherlands.; GROW - School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands., Vane MLG; Department of Surgical Oncology, Maastricht University Medical Centre, P.O. Box 5800, 6202 AZ, Maastricht, The Netherlands. marissa.vane@gmail.nl.; GROW - School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands. marissa.vane@gmail.nl., van Nijnatten TJA; Department of Radiology and Nuclear Medicine, Maastricht University Medical Centre, Maastricht, The Netherlands., van Maaren MC; Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.; Department of Health, Technology and Services Research, Technical Medical Centre, University of Twente, Enschede, The Netherlands., Goorts B; Department of Surgical Oncology, Maastricht University Medical Centre, P.O. Box 5800, 6202 AZ, Maastricht, The Netherlands.; GROW - School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands.; Department of Radiology and Nuclear Medicine, Maastricht University Medical Centre, Maastricht, The Netherlands., Heuts EM; Department of Surgical Oncology, Maastricht University Medical Centre, P.O. Box 5800, 6202 AZ, Maastricht, The Netherlands.; GROW - School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands., Strobbe LJA; Department of Surgical Oncology, Canisius Wilhelmina Ziekenhuis, Nijmegen, The Netherlands., Smidt ML; Department of Surgical Oncology, Maastricht University Medical Centre, P.O. Box 5800, 6202 AZ, Maastricht, The Netherlands.; GROW - School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands.

Publikováno v: Breast cancer research and treatment [Breast Cancer Res Treat] 2021 Apr; Vol. 186 (3), pp. 863-870. Date of Electronic Publication: 2021 Mar 10.

Extracapsular extension in the positive sentinel lymph node: a marker of poor prognosis in cT1-2N0 breast cancer patients?

Autor: Vane MLG; Department of Surgical Oncology, Maastricht University Medical Centre, P.O. Box 5800, 6202 AZ, Maastricht, The Netherlands. marissa.vane@gmail.com.; GROW - School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands. marissa.vane@gmail.com., Willemsen MA; Department of Surgical Oncology, Maastricht University Medical Centre, P.O. Box 5800, 6202 AZ, Maastricht, The Netherlands., van Roozendaal LM; Department of Surgery, Zuyderland Medical Centre, Heerlen, The Netherlands., van Kuijk SMJ; Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre, Maastricht, The Netherlands., Kooreman LFS; GROW - School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands.; Department of Pathology, Maastricht University Medical Centre, Maastricht, The Netherlands., Siesling S; Department of Research, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.; Department of Health Technology and Services Research, MIRA Institute for Biomedical Science and Technical Medicine, University of Twente, Enschede, The Netherlands., de Wilt HHW; Department of Surgical Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands., Smidt ML; Department of Surgical Oncology, Maastricht University Medical Centre, P.O. Box 5800, 6202 AZ, Maastricht, The Netherlands.; GROW - School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands.

Publikováno v: Breast cancer research and treatment [Breast Cancer Res Treat] 2019 Apr; Vol. 174 (3), pp. 711-718. Date of Electronic Publication: 2019 Jan 04.

TNM classification and the need for revision of pN3a breast cancer.

Autor: van Nijnatten TJA; Department of Radiology and Nuclear Medicine, Maastricht University Medical Center+, Maastricht, The Netherlands; Department of Surgery, Maastricht University Medical Center+, Maastricht, The Netherlands; GROW - School for Oncology and Developmental Biology, Maastricht University Medical Center+, Maastricht, The Netherlands. Electronic address: Thiemovn@gmail.com., Moossdorff M; Department of Surgery, Maastricht University Medical Center+, Maastricht, The Netherlands; GROW - School for Oncology and Developmental Biology, Maastricht University Medical Center+, Maastricht, The Netherlands., de Munck L; Department of Research, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands., Goorts B; Department of Radiology and Nuclear Medicine, Maastricht University Medical Center+, Maastricht, The Netherlands; Department of Surgery, Maastricht University Medical Center+, Maastricht, The Netherlands; GROW - School for Oncology and Developmental Biology, Maastricht University Medical Center+, Maastricht, The Netherlands., Vane MLG; Department of Surgery, Maastricht University Medical Center+, Maastricht, The Netherlands; GROW - School for Oncology and Developmental Biology, Maastricht University Medical Center+, Maastricht, The Netherlands., Keymeulen KBMI; Department of Surgery, Maastricht University Medical Center+, Maastricht, The Netherlands., Beets-Tan RGH; GROW - School for Oncology and Developmental Biology, Maastricht University Medical Center+, Maastricht, The Netherlands; Department of Radiology, The Netherlands Cancer Center, Amsterdam, The Netherlands., Lobbes MBI; Department of Radiology and Nuclear Medicine, Maastricht University Medical Center+, Maastricht, The Netherlands., Smidt ML; Department of Surgery, Maastricht University Medical Center+, Maastricht, The Netherlands; GROW - School for Oncology and Developmental Biology, Maastricht University Medical Center+, Maastricht, The Netherlands.

Publikováno v: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2017 Jul; Vol. 79, pp. 23-30.